ChromoCure Gains More Industry Support as Its Technology Shown Superior to 'Biomarkers': Biomarker Assays Diagnostics "Not Produ
March 04 2010 - 8:30AM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) -- ChromoCure's role in Cancer
Detection and Research received more support from a report of the
Cambridge Healthtech Institute's (CHI) "Biomarker Assay
Development" conference held in late January in San Diego.
As reported in the March issue of Genetic Engineering &
Biotechnology News (Vol. 30, No. 5): "pathway biomarkers have not
produced hoped-for results in predicting patients' tumor
sensitivity to targeted therapy"... and "[the] technologies also
have not lived up to expectations."
Research has conclusively and irrefutably demonstrated
aneuploidy as a more accurate predictor of cancer than
cytological/histological analysis or genetic marker-based
diagnostics that are the only other methods in existence today.
ChromoCure's systems measure aneuploidy as the sole means of
detecting cancer presence and measuring cancer progression. The
system has a 100% effective accuracy rate.
Biomarkers, when supposedly 'effective,' detect either specific
proteins generated by cancer, or a genetic anomaly. BOTH of these
effects are products of aneuploidy and BOTH effects are transient
due to the evolutionary, ever-changing aspect of aneuploidy. The
correlation of 'markers' to the presence of cancer is an effect of
the ever-changing chromosomal structures. That's why 'biomarker'
approaches are not reliably effective and eventually become
completely ineffective. Also of note: the transitional nature of
chromosomal imbalance is the reason cancer eventually becomes
'immune' to chemotherapy. The drug targets a certain type of cell
configuration. That configuration is momentary in the progression
of aneuploidy (cancer). The configuration is also only a PORTION of
the population of cells with aneuploidy. Detection of specific
aspects of the cancer population is inaccurate and not reliable, as
so much was admitted at the CHI conference. Therefore, detection of
aneuploidy is 100% effective. It is this unique aspect of cancer
present at all stages and in all cancers that is detected by the
company's systems.
The Company's proprietary Chromosomal Scanner systems have
proven accurate and efficient in the measurement of the unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has been proven
to have an effective accuracy of 100% for all cancers at all
stages. This is superior to biomarker detection in every measurable
way. The Company recently published its collaborative clinical
testing with a major cancer clinic.
The Company's focus on cancer research is further underscored by
recent major clinical publications that both validate ChromoCure's
chromosomal/aneuploidy theory of cancer and establish the company's
detection approach as the forefront of both cancer detection and
research.
The company's technology and related research opens the way for
non-invasive and non-toxic solutions to cancer therapeutics and
disease eradication. ChromoCure's scanner technologies include
proprietary designs, processes, and algorithms centered on
chromosomal imbalance. They provide the foundation for significant
advantages in delivering important results in diagnosis, therapy
and cure.
The Company invites industry and scientific collaboration
through its "Project Boveri: Find the Cure" initiative.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary CS200 Chromosomal Scanner has been proven accurate and
efficient in the measurement of the unique genomic characteristic
found in 100% of all cancers and never found in normal cells. The
Company's detection technology has an effective accuracy of 100%
for all cancers at all stages. The Company believes its technology
will become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer
cure and therapeutics research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Sep 2023 to Sep 2024